ES2158126T3 - Quinoxalinadionas antagonistas del receptor nmda. - Google Patents

Quinoxalinadionas antagonistas del receptor nmda.

Info

Publication number
ES2158126T3
ES2158126T3 ES95931989T ES95931989T ES2158126T3 ES 2158126 T3 ES2158126 T3 ES 2158126T3 ES 95931989 T ES95931989 T ES 95931989T ES 95931989 T ES95931989 T ES 95931989T ES 2158126 T3 ES2158126 T3 ES 2158126T3
Authority
ES
Spain
Prior art keywords
sub
sup
rent
united
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95931989T
Other languages
English (en)
Inventor
Charles Eric Mowbray
Alan Stobie
David John Bull
Christopher Lee Carr
Michael Johnathan Fray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research and Development Co NV SA filed Critical Pfizer Research and Development Co NV SA
Application granted granted Critical
Publication of ES2158126T3 publication Critical patent/ES2158126T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPUESTOS DE FORMULA (I) EN DONDE R 1 Y R 2 SON CADA UNO INDEPENDIENTEMENTE F, CL, BR, CH{SUB,3}, CH{SUB,2}CH{SUB,3} O CF{SUB,3}; R{SUP,3} ES H, CH{SUB,3} O CH{SUB,2}CH{SUB,3}; Y X ES UN GRUPO HETEROCICLICO DE 5 MIEMBROS QUE CONTIENE HASTA CUATRO ATOMOS DE NITROGENO, UNIDOS MEDIANTE UN ATOMO DE NITROGENO, ESTANDO EL MENCIONADO GRUPO OPCIONALMENTE BENZOFUSIONADO Y/O SUSTITUIDO POR ALQUILO C{SUB,1}-C{SUB,6} O (()CH{SUB,2}()){SUB,N}NR{SUP,4}R{SUP,5}, EN DONDE N ES UN ENTERO DE 1 A 5 Y R{SUP,4} Y R{SUP,5} SON CADA UNO INDEPENDIENTEMENTE H, ALQUILO C{SUB,1}-C{SUB,6}, CICLOALQUILO C{SUB,3}-C{SUB,6} O ALQUILO C{SUB,1}-C{SUB,4} SUSTITUIDO POR FENILO O PIRIDILO, O R{SUP,4} Y R{SUP,5} ESTAN UNIDOS PARA FORMAR, JUNTO CON EL ATOMO DE NITROGENO AL QUE ESTAN UNIDOS, UN GRUPO DE PIRROLIDINA, PIPERIDINA, PIPERAZINA, PIPERAZINA N-(()ALQUILO C{SUB,1}C{SUB,4}()), MORFOLINO O AZEPINA; Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, SON ANTAGONISTAS DE NMDA DE UTILIDAD EN EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS AGUDOS, P.EJ., QUE SURGEN DE APOPLEJIA O TRAUMA CRANEOENCEFALICO Y EN TRASTORNOS NEUROLOGICOS CRONICOS, P.EJ., DEMENCIA SENIL Y ENFERMEDAD DE ALZHEIMER.
ES95931989T 1994-09-13 1995-09-01 Quinoxalinadionas antagonistas del receptor nmda. Expired - Lifetime ES2158126T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9418443A GB9418443D0 (en) 1994-09-13 1994-09-13 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2158126T3 true ES2158126T3 (es) 2001-09-01

Family

ID=10761258

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95931989T Expired - Lifetime ES2158126T3 (es) 1994-09-13 1995-09-01 Quinoxalinadionas antagonistas del receptor nmda.

Country Status (14)

Country Link
US (1) US5783572A (es)
EP (1) EP0781279B1 (es)
JP (1) JP2898097B2 (es)
AT (1) ATE202099T1 (es)
CA (1) CA2199845C (es)
DE (1) DE69521323T2 (es)
DK (1) DK0781279T3 (es)
ES (1) ES2158126T3 (es)
FI (1) FI113471B (es)
GB (1) GB9418443D0 (es)
GR (1) GR3036270T3 (es)
MX (1) MX9701894A (es)
PT (1) PT781279E (es)
WO (1) WO1996008485A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US5874426A (en) * 1995-06-07 1999-02-23 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
GB9605027D0 (en) 1996-03-09 1996-05-08 Pfizer Ltd Quinoxalinediones
AU5367598A (en) * 1996-11-25 1998-06-22 Warner-Lambert Company Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6172065B1 (en) 1997-03-04 2001-01-09 Warner-Lambert Company Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
TW526195B (en) 1997-06-10 2003-04-01 Novartis Ag Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use
DE19936521A1 (de) * 1999-08-06 2001-02-15 Gruenenthal Gmbh Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
EP2425846A1 (en) * 2004-12-23 2012-03-07 Voyager Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
AU2011343966B2 (en) * 2010-12-13 2017-03-16 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
DE102015011861B4 (de) * 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
DK715888D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
DK0647137T3 (da) * 1992-06-22 2008-12-08 State Of Oregon Through Oregon Glycinreceptorantagonister og anvendelse deraf

Also Published As

Publication number Publication date
ATE202099T1 (de) 2001-06-15
WO1996008485A1 (en) 1996-03-21
JP2898097B2 (ja) 1999-05-31
FI113471B (fi) 2004-04-30
DE69521323T2 (de) 2001-09-20
FI971026A0 (fi) 1997-03-12
GR3036270T3 (en) 2001-10-31
GB9418443D0 (en) 1994-11-02
JPH09511523A (ja) 1997-11-18
FI971026A7 (fi) 1997-03-12
CA2199845A1 (en) 1996-03-21
PT781279E (pt) 2001-09-28
MX9701894A (es) 1997-06-28
CA2199845C (en) 2000-08-01
DE69521323D1 (de) 2001-07-19
EP0781279A1 (en) 1997-07-02
EP0781279B1 (en) 2001-06-13
US5783572A (en) 1998-07-21
DK0781279T3 (da) 2001-09-03

Similar Documents

Publication Publication Date Title
AR030189A1 (es) Compuesto de benzotiazol, uso del mismo para preparar una composicion farmaceutica y dicha composicion farmaceutica
ES2111650T3 (es) Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
MX9304996A (es) Heterociclos no-aromaticos que contienen bencilamino nitrogeno substituido.
ES2135414T3 (es) Antagonistas del receptor 5-ht4.
ATE86110T1 (de) Behandlung von gastrointestinalkrankheiten durch anwendung von 5-ht3-antagonisten.
DOP2004001062A (es) Compuestos utiles en terapia
NO953447D0 (no) Nye 4-aminopyridiner, fremgangsmåte for deres fremstilling samt legemidler inneholdende disse
AR041508A1 (es) Compuestos con actividad en los receptores de glutamato metabotropicos
ATE541833T1 (de) Stickstoff-enthaltende verbindungen mit kinasehemmender wirkung sowie diese enthaltende medikamente
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
ES2118962T3 (es) Derivados dimeros de piperidina, tetrahidropiridina y piperazina.
ECSP034712A (es) Ciclobuteno-1.2-dionas 3,4-di-substituidas como antagonistas del receptor quimiocina cxc
AR006360A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion.
DK0491664T3 (da) Indolderivater som serotonin-antagonister
MX9206847A (es) Derivados de indolpirrolcarbazol, proceso para su preparacion y medicamento que los contiene
AR028812A1 (es) Compuestos de amida, utiles para potenciar la actividad colinergica; proceso para prepararlos; composiciones farmaceuticas formuladas con dichos compuestos; uso de dichos compuestos para preparar dichas composiciones y/o prevenir la amnesia y/o demencia y metodo para tratar dichas enfermedades
ES2093399T3 (es) Nuevos derivados de acido fosfono-succinico, procedimiento para su preparacion y medicamentos que contienen estos compuestos.
UY25079A1 (es) Derivados de azetidinas útiles como antagonistas de las taquicininas y sus intermediarios
MX9701894A (es) Quinoxalinadionas antagonistas del receptor n-metil-d-aspartato.
ES2159380T3 (es) Compuestos de (n-(piridinilmetil)-heterociclo)ilidenamina como agentes que se unen al receptor nicotinico de acetilcolina.
MX9205816A (es) Acidos benzimidazolfosfono-amino y proceso para su preparacion.
UY25236A1 (es) Hidrohalogenuros de 1'-(4-(1-(4-fluorfenil)-1-h-indol-3-il(- 1-butil)-espiro(isobenzofuran-1(3h),4'-piperidina)
ES2117797T3 (es) Procedimiento para la preparacion de compuestos de benzodiazepina utilizados como antagonistas de la cck o de la gastrina.
ES2081314T3 (es) Compuestos de diaminoetileno.
IT1243719B (it) Miscela stabilizzante per composti ad attivita' fotocromatica

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 781279

Country of ref document: ES